Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

TYO:4570 Revenue

Immuno-Biological Laboratories had revenue of 286.00M JPY in the quarter ending June 30, 2026, with 35.55% growth. This brings the company's total for the last twelve months to 1.08B, up 13.46% year-over-year. In the fiscal year ending March 31, 2026, Immuno-Biological Laboratories had annual revenue of 1.00B with 3.61% growth. That makes Immuno-Biological Laboratories the 38,896th largest company in the world by revenue and 3,781st in Japan.

• Revenue (ttm): 1.08B
• Revenue Growth: +13.46%
• P/S Ratio: 8.69
• Revenue / Employee: 19.98M
• Employees: 54
• Market Cap: 9.38B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Antibody Related Business 1.00B 99.7%
• Cosmetics Related 2.68M 0.3%

By Geography

Chart

• Japan 593.22M 59.0%
• United States 180.37M 17.9%
• Others 139.10M 13.8%
• China 92.30M 9.2%

Fiscal year ended Mar 31, 2026 See the full TYO:4570 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	1.00B	35.00M	3.61%
Mar 31, 2025	969.00M	153.00M	18.75%
Mar 31, 2024	816.00M	22.00M	2.77%
Mar 31, 2023	794.00M	147.00M	22.72%
Mar 31, 2022	647.00M	45.00M	7.48%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error